Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.71 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5153452 | 1.00 | USP30 (0.71) | USP30GPR119PIK3CDKDM4EPKM | |
| SCHEMBL21409063 | 1.00 | USP30 (0.71) | USP30GPR119PIK3CDKDM4EPKM | |
| SCHEMBL5268593 | 0.92 | GPR119 (0.65) | USP30GPR119KDM4EPKMMEN1 | |
| SCHEMBL22278158 | 0.89 | USP30 (0.67) | USP30GPR119KDM4EPKMPRMT5 | |
| SCHEMBL5545000 | 0.88 | USP30 (0.58) | USP30GPR119PIK3CDKMT2A | |
| SCHEMBL240368 | 0.88 | USP30 (0.58) | USP30GPR119PIK3CDKMT2A | |
| SCHEMBL5544755 | 0.88 | USP30 (0.58) | USP30GPR119PIK3CDKMT2A | |
| SCHEMBL699609 | 0.88 | GPR119 (0.58) | USP30GPR119PIK3CD | |
| SCHEMBL6189661 | 0.88 | GPR119 (0.58) | USP30GPR119PIK3CDCHRM3 | |
| SCHEMBL20179924 | 0.88 | GPR119 (0.58) | USP30GPR119PIK3CDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2024-04-18 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323349-A1 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-8846711-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846711-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2501693-B1 | AZA HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS BACTERICIDES | FAB PHARMA SAS (FR) | 2014-09-17 | — | — | EP | disclosed |
| EP-2501693-B1 | AZA HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS BACTERICIDES | FAB PHARMA SAS (FR) | 2014-09-17 | — | — | EP | disclosed |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2501693-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB Pharma SAS (FR) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | USP30 4587/4885GPR119 348/4885PIK3CD 2473/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | USP30 2752/4885GPR119 2930/4885PIK3CD 3205/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | USP30 2752/4885GPR119 2930/4885PIK3CD 3205/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | USP30 1569/4885GPR119 2263/4885PIK3CD 3853/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | USP30 2818/4885GPR119 1398/4885PIK3CD 1188/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | USP30 2752/4885GPR119 2930/4885PIK3CD 3205/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | USP30 908/4885GPR119 2955/4885PIK3CD 3481/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | USP30 3735/4885GPR119 4204/4885PIK3CD 2674/4885 |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | USP30 764/4885GPR119 3612/4885PIK3CD 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.